The Tissue and Outcomes Core is responsible for identifying women diagnosed with breast cancer at the University of California, San Francisco (UCSF, including San Francisco General Hospital - SFGH) and the California Pacific Medical Center (CPMC), collecting fresh tissue (at UCSF and SFGH) and paraffin blocks (at all sites), collecting and entering clinical, epidemiologic, pathology and follow-up information into a database (for all sites), and distributing breast tissue with associated clinical information to SPORE investigators. Tissue is collected prospectively at the time of surgery and banked as fresh-frozen cassettes or formalin-fixed blocks. Fresh tissue for culture is also collected. The Core also identifies archival formalin blocks for studies and coordinates with other tumor banks to obtain additional material for investigators. Tissues are reviewed by Core pathologists as needed for histopathologic features and to confirm the presence and percentage of tumor cells. Requests for tissue and clinical data are approved by a Tissue &Data Utilization Committee, which reviews requests for project feasibility and priorities. The Core extracts DMA and RNA for studies and coordinates preparation of tissue microarray blocks. In addition to baseline data collected on women with newly diagnosed breast cancer, the Core obtains informed consent for tissue use and follow-up information to determine disease status on all women in the database by mailing women a survey every 18-months. Annual linkage is done with the Northern California Surveillance, Epidemiology, and End Results (SEER) program to determine vital status and disease specific mortality. Baseline and follow-up information from 4,239 women with breast cancer (3,240 invasive and 902 DCIS cases) diagnosed at UCSF, CPMC, or SFGH with a median follow-up time of six years are currently in a relational database. The overall goal for the next five years is to maintain and expand the tissue bank and database so that it can continue to serve as a resource to conduct high quality, clinically significant translational research and to acquire breast cancer outcomes for study populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058207-18
Application #
8377734
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
2013-11-30
Budget Start
2012-01-20
Budget End
2012-11-30
Support Year
18
Fiscal Year
2012
Total Cost
$291,620
Indirect Cost
$69,203
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Bolan, Patrick J; Kim, Eunhee; Herman, Benjamin A et al. (2017) MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging 46:290-302
Campbell, Michael J; Baehner, Frederick; O'Meara, Tess et al. (2017) Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat 161:17-28
Olow, Aleksandra; Chen, Zhongzhong; Niedner, R Hannes et al. (2016) An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer. Cancer Res 76:1733-45
Hu, Zhi; Mao, Jian-Hua; Curtis, Christina et al. (2016) Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Res 18:70
Takai, Ken; Le, Annie; Weaver, Valerie M et al. (2016) Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget 7:82889-82901
Malkov, Serghei; Shepherd, John A; Scott, Christopher G et al. (2016) Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status. Breast Cancer Res 18:122
Gu, Shenda; Hu, Zhi; Ngamcherdtrakul, Worapol et al. (2016) Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget 7:14727-41
Molinaro, Annette M; Sison, Jennette D; Ljung, Britt-Marie et al. (2016) Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy. Breast Cancer Res Treat 157:351-361
Drake, Christopher R; Estévez-Salmerón, Luis; Gascard, Philippe et al. (2015) Towards aspirin-inspired self-immolating molecules which target the cyclooxygenases. Org Biomol Chem 13:11078-86

Showing the most recent 10 out of 337 publications